Drug recall D-0388-2023
Product
Doxazosin Tablets USP, 4 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-213-01 UPC 3 16729 21301 1; b) 1,000-count bottle NDC 16729-213-17 UPC 3 16729 21317 2; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA
Reason for recall
CGMP Deviations: recalling drug products following an FDA inspection.
Lots and codes
Batches: a) R2200352, Exp. Date 5/31/2024; R2200356, Exp. Date 8/31/2024; R2200357, Exp. Date 8/31/2024; R2200633, Exp. Date 4/30/2025; R2200634, Exp. Date 4/30/2025; b) R2200677,Exp. Date 8/31/2024; R2200572,Exp. Date 4/30/2025; R2200571, Exp. Date 4/30/2025; R2200646, Exp. Date 4/30/2025;
Recall details
- Recalling firm
- Accord Healthcare, Inc., Durham, NC
- Quantity
- 75,190 bottles
- Distribution
- United States including Puerto Rico and Canada
- Type
- Voluntary: Firm initiated
- Recall initiated
- February 7, 2023
- Terminated
- April 22, 2024
Related products
- Doxazosin – drug information
- NDC 16729-211 Doxazosin · Doxazosin Mesylate 1 mg/1 · Accord Healthcare Inc.
- NDC 16729-213 Doxazosin · Doxazosin Mesylate 4 mg/1 · Accord Healthcare Inc.
- NDC 16729-414 Doxazosin · Doxazosin Mesylate 2 mg/1 · Accord Healthcare Inc.
- NDC 16729-415 Doxazosin · Doxazosin Mesylate 8 mg/1 · Accord Healthcare Inc.